"Companion diagnostics": Has their time come and gone?

Clinical Cancer Research

Volumn 20, Issue 17, 2014, Pages 4422-4424

  Hirsch, Fred R ^a   Bunn, Paul A ^a   Herbst, Roy S ^b  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ONARTUZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; SCATTER FACTOR RECEPTOR; TUMOR MARKER; ANTINEOPLASTIC AGENT; MET PROTEIN, HUMAN; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE;

ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVAL; COMPANION DIAGNOSTICS; FLUORESCENCE IN SITU HYBRIDIZATION; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; MALE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; ERLOTINIB HYDROCHLORIDE; FEMALE; HUMANS; MALE; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES;

EID: 84921380258     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0932     Document Type: Article

References (10)

1. Koeppen H, Yu W, Zha J, Pandita A, Penuel E, Rangell L, et al. Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib ± onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit. Clin Cancer Res 2014;20:4488-98.
2. Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH Jr, Blumenschein JR, et al. Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small cell lung cancer. J Clin Oncol 2013:31:4105-14.
3. Shepherd FA, Rodrigues PJ, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005;353:123-32.
4. Engelman JA, Janne PA. Mechanisms of acquired resistance to epidernmal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008;14: 2895-9.
5. Spigel DR, Edelman MJ, O'Byrne K, Paz-Ares L, Shames D, Yu W, et al. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb and IV NSCLC: results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM 4971g) global trial. J Clin Oncol 32:5s, 2014 (suppl; abstr 8000).
6. Camidge DR, Ou SHI, Shapiro G, Otterson G, Villaruz L, Villalona-Calero M, et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). J Clin Oncol 32:5s, 2014 (suppl; abstr 8001).
7. Wynes MW, Sholl LM, Dietel M, Schuuring E, Tsao MS, Yatabe Y, et al. An international interpretation study using ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol 2014;9:631-8.
8. Ren S, Hirsch FR, Varella-Garcia M, Aisner DL, Boyle T, Zhou C, et al. Atypical negative ALK break-apart FISH harboring a crizotinibresponsive ALK-rearrangement in non-small cell lung cancer. J Thorac Oncol 2014;9:e21-3.
9. Peled N, Palmer G, Hirsch FR, Wynes MW, Ilouze M, Varella-Garcia M, et al. Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small cell lung cancer. J Thorac Oncol 2012;7:e14-6.
10. Malik SM, Pazdur R, Abrams JS, et al. Consensus report of a joint NCI thoracic malignancies steering committee-FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to "Master Protocols" in lung cancer. J Thorac Oncol. In press.